ArticleGenes & cancer2010
Involvement of interleukin-6 and androgen receptor signaling in pancreatic cancer.
Article in Genes & cancer, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.
- Mechanisms of obesity- and diabetes mellitus-related pancreatic carcinogenesis: a comprehensive and systematic review.Signal transduction and targeted therapy · 2023Pooled it
- Cancer-associated fibroblast-derived interleukin-6 as a key driver of epithelial-mesenchymal transition and metastasis in oral squamous cell carcinoma.Journal of dental sciences · 2026Article
- Acute myeloid leukaemia cells express high levels of androgen receptor but do not depend on androgen signaling for survival.Leukemia · 2025Article
- Targeting STAT3 signaling pathway by curcumin and its analogues for breast cancer: A narrative review.Animal models and experimental medicine · 2024Review
- Review
- Retrospective study of testosterone deficiency and symptom burden in patients with pancreatic cancer.Translational andrology and urology · 2023Article
- Integrated genomic analysis to identify druggable targets for pancreatic cancer.Frontiers in oncology · 2022Article
- The role of IL-6/JAK2/STAT3 signaling pathway in cancers.Frontiers in oncology · 2022Review
- Heterogeneous Pancreatic Stellate Cells Are Powerful Contributors to the Malignant Progression of Pancreatic Cancer.Frontiers in cell and developmental biology · 2021Review
- Blood-based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Pancreatic Cancer and its Value to Guide Clinical Treatment.Journal of Cancer · 2020Article
- Prognostic and Therapeutic Significance of Androgen Receptor in Patients with Gastric Cancer.OncoTargets and therapy · 2020Article
- A reporter mouse for non-invasive detection of toll-like receptor ligands induced acute phase responses.Scientific reports · 2019Article
- Overexpression of the androgen receptor in human hepatoma cells and its effect on fatty acid metabolism.Oncology letters · 2017Article
- Androgen Receptor Could Be a Potential Therapeutic Target in Patients with Advanced Hepatocellular Carcinoma.Cancers · 2017Article
- Review
- Peroxisome proliferator activated receptors at the crossroad of obesity, diabetes, and pancreatic cancer.World journal of gastroenterology · 2016Review
- The androgen receptor as an emerging target in hepatocellular carcinoma.Journal of hepatocellular carcinoma · 2015Review
- Role of non-genomic androgen signalling in suppressing proliferation of fibroblasts and fibrosarcoma cells.Cell death & disease · 2014Article
- Knockdown of glucose-regulated protein 78 enhances poly(ADP-ribose) polymerase cleavage in human pancreatic cancer cells exposed to endoplasmic reticulum stress.Oncology reports · 2014Article
- Nuclear receptors and pathogenesis of pancreatic cancer.World journal of gastroenterology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer remains one of the "difficult-to-treat" cancers. Signaling of androgen receptor (AR), one of the nuclear receptors, in the pancreas may be related to carcinogenesis. Higher interleukin-6 (IL-6) levels have been observed in pancreatic cancer patients. It is also well known that IL-6 affects the AR signaling pathway and that AR is important for cell migration activities. We demonstrated that IL-6 enhances the phosphorylation of STAT3 and MAPK, which in turn enhances AR-mediated transcription in pancreatic cancer cell lines. This activity was blocked by a pharmacological inhibitor of the JAK/STAT signaling pathway, AG490, and one of the MAPK signaling pathways, U0126. IL-6 also enhances pancreatic cancer cell migration in the presence of AR. This activity is blocked by AR-siRNA. IL-6 acts as a positive regulator in AR signaling, providing further insight into the progression of pancreatic carcinogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.